Home >> Industry News >> All The News
  • Also available via:

World's best virtual tryon released with advanced features PDF
Submit Your News
Product News
Friday, 09 January 2009
The new version of vmo, VirtualMirrorOnline, has been released today. VMO is the world's best virtual tryon module that enables a superior online shopping experience to customers of sunglasses and optical frames. It has the most advanced calibration system incorporated that provides for automatic facial and pupil detection. As a consequence, customers are provided with the most advanced and easiest to use tryon system available today. The module can be plugged into any website. It therefore is a perfect tool for vendors to showcase their latest collection, practices to engage their patients in trying on their latest available collection, or online eyewear sites to increase the online shopping experience.

For more information and for an online demo of vmo contact us at: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Carl Zeiss takes on Vuzix at Macworld 2009 PDF
Submit Your News
Product News
Friday, 09 January 2009
Carl Zeiss has announced a new version of its Cinemizer video eyewear at Macworld 2009 in San Francisco on Tuesday.

The company believes that outside of the lens business consumers want goggles that enable them to enjoy video at home or on the go.

That viewpoint is very different from competing eyewear maker Vuzix whose design and approach is heading more towards a heads up display approach. It has just announced a more sunglasses styled product at CES in Las Vegas.

The Zeiss Cinemizer plus has according to Klavehn been updated and improved over the original Zeiss Cinemizer video eyewear released last year in Germany.

The Cinemizer combines high-resolution LCD screens with individual diopter focus adjustment (-3.5 to +3.5D) allowing for users who wear glasses to still focus on the screen. The eyewear also adds on-ear headphones and the ability to override them with your own headphones.

Carl Zeiss says it is actively lobbying Hollywood studios to offer consumer versions of the 3D movies they are creating. Of 5545 (indoor) cinemas in the US, there are 1068 3D capable screens, which are showing a rapidly growing number of 3D movies. But currently there are very few options to bring the 3D experience into the consumer realm.

The Cinemizer plus will be available in the USA, UK and Germany from March 2009 with an expected price of a rather expensive AUD$650.
Recall of Ophthalmic Surgical Device in US PDF
Submit Your News
International News
Thursday, 08 January 2009
The U.S. Food and Drug Administration announced a Class I recall of lot no. UD30654 of Healon D, an ophthalmic viscosurgical device (OVD) manufactured by Advanced Medical Optics Inc. (AMO) of Santa Ana, Calif.

OVDs are viscoelastic materials used to maintain space in the eye during surgery. Typically, OVDs are pre-packaged in a syringe and are applied using a small tube.

On Oct. 30, 2008, AMO voluntarily recalled all 4,439 units of Healon D lot no. UD30654 of Healon D, due to complaints of inflammation after eye surgery, including Toxic Anterior Segment Syndrome (TASS). At that time, AMO informed customers of the number and nature of adverse event reports associated with OVD from that lot, and included a fax reply form for quick communication.

However, as of December 3, 2008, AMO had retrieved only 964 units of the 1,450 that had been distributed in the United States.

AMO received 66 adverse event reports associated with the recalled products. Tests of this lot revealed elevated levels of endotoxin, which has been associated with post-operative intraocular inflammation and TASS.

TASS is a post-operative, acute inflammation of the anterior segment of the eye (the front third of the eye including the cornea, iris and lens). TASS has been linked to solutions and devices used during eye surgery, such as OVDs, intraocular lenses and irrigation solutions.

The FDA urges anyone in possession of any units from the recalled lot, whether units were purchased from the company or provided as a sample by a sales representative, to remove them from inventory, and contact AMO at 1-877-AMO-4Life to make arrangements for return. The lot number of the device is displayed on the side panel of each unit.
See by Three announces research findings PDF
Submit Your News
Ophthalmology and Optometry
Wednesday, 07 January 2009
The Children’s Eye Foundation’s program announces the completion of the first phase of its national, US, research project. The program advocates effective screening of children so they will “see by three,” and aimed to demonstrate that this screening can be done in what’s called the “medical home,” that is any pediatrician’s office or health clinic.

Dr. Chamblee, vice president of programs, said, “It’s very exciting to complete the first phase of See by Three and we are proceeding with the next step, publishing research papers to the medical community.” See by Three’s third phase will be a nationwide public awareness campaign to parents and health care providers. Dr. Chamblee goes on to say that, “The first phase of this program has shown that screening children in the medical home provides a very positive outcome for children.”

As referenced in the recent article by Contemporary Pediatrics, titled “When you’re seeing a child for a well visit, can they see you?”, it is important to note that amblyopia is truly a disorder of the brain that affects sight.

Fast facts:
  • More vision is lost to amblyopia in the first 45 years of life that to all other conditions combined
  • Amblyopia is the most common cause of vision loss in children
  • Only one third of children receive a vision screening by age 5
  • Amblyopia costs an estimated US$32 billion in lost productivity each year in the US
Vision Group non-binding, conditional offers PDF
Submit Your News
Australian News
Tuesday, 06 January 2009
Vision Group Holdings Limited (the "Company") advises that it has received a number of non-binding, conditional offers to acquire the Company. These offers value the Company appreciably above the current share price. The offers received contemplate an ongoing and significant equity position for the existing doctor partners in the Company and the acquisition of all other shareholders for cash consideration. The Company’s doctor partners together with management hold approximately one third of the Company's issued capital.

The Board has agreed to work exclusively with the party that delivered the most compelling proposal to further examine a number of the key offer conditions so as to determine whether a satisfactory outcome can be achieved for all shareholders. There can be no assurance that a binding offer on acceptable terms will result from this process.

The Company’s core business and cash flow remains strong and the Company continues to make good progress in doctor partner contract renegotiations.
<< Start < Prev 221 222 223 224 225 226 227 228 229 230 Next > End >>

Page 226 of 309